InvestorsHub Logo
Followers 0
Posts 37
Boards Moderated 0
Alias Born 10/16/2013

Re: stockweiser post# 6090

Saturday, 01/10/2015 5:49:49 PM

Saturday, January 10, 2015 5:49:49 PM

Post# of 10489
From my understanding the way the trial is set up, the interim analysis will only be looking at safety and futility. Which means the only public statement released will be to continue the trial or stop the trial due to safety and/or futility. This does not mean the data for efficacy isn't reviewed, it is!
However, I'm hoping the data at the interim analysis is overwhelming enough that regulators consider it unethical to prevent this set of BC patients from receiving NeuVax.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.